Skip to main content
Top
Published in: Reactions Weekly 1/2024

01-04-2024 | Urothelial Cancer | Case report

Enfortumab-vedotin

Steven-Johnson syndrome/toxic epidermal necrolysis-like blistering reaction

Published in: Reactions Weekly | Issue 1/2024

Login to get access

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literature
go back to reference Khanjar B, et al. Enfortumab vedotin toxic epidermal necrolysis-like blistering dermatosis: A case series and review of the literature. JAAD Case Reports 43: 40-50, Jan 2024. Available from: URL: https://dx.doi.org/10.1016/j.jdcr.2023.10.025 Khanjar B, et al. Enfortumab vedotin toxic epidermal necrolysis-like blistering dermatosis: A case series and review of the literature. JAAD Case Reports 43: 40-50, Jan 2024. Available from: URL: https://​dx.​doi.​org/​10.​1016/​j.​jdcr.​2023.​10.​025
Metadata
Title
Enfortumab-vedotin
Steven-Johnson syndrome/toxic epidermal necrolysis-like blistering reaction
Publication date
01-04-2024
Publisher
Springer International Publishing
Published in
Reactions Weekly / Issue 1/2024
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-56830-2

Other articles of this Issue 1/2024

Reactions Weekly 1/2024 Go to the issue

Case report

Sirolimus

Case report

Thiamazole

Case report

Testosterone